PRF Technologies (PRFX)
Develops sustained-release therapies and software for solar-asset monitoring and optimization.
Something off on this page? Send us feedback.
Develops sustained-release drug-delivery candidates alongside DeepSolar software for solar-asset monitoring, forecasting and optimization. The asset-light model relies on external clinical and manufacturing partners, with no approved pharmaceutical product and an early solar business.
Operates Clinical Development and Solar segments. Clinical Development includes LayerBio's OcuRing platform, led by OcuRing-K, a bio-erodible ring designed to deliver ketorolac locally after cataract surgery, and PRF-110, an investigational extended-release ropivacaine solution for surgical wounds. OcuRing-K was preparing for its next clinical trial, while PRF-110 was de-emphasized after missing its pivotal endpoint.
DeepSolar connects with SCADA systems to monitor solar assets, compare potential with actual production, diagnose equipment issues, prioritize maintenance and automate reporting. Its early commercial engagements include Romania and Israel, while its pharmaceutical candidates target United States regulatory pathways. Neither drug candidate is approved, and clinical development and prospective commercial manufacturing depend on third-party partners.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $4.1M · Total debt $21.0K · Total assets $12.0M · Shareholders' equity $8.5M
- Revenue
- $17.0K
- Operating income
- −$5.1M
- Net income
- −$4.8M
No dividends on record.
| Institutions4 holders · as of Mar 31, 2026 | 94.75% | 15.7K ADS | |
| Otherremainder | 5.25% | 872 ADS |
16.6K ADS (1 ADS = 10 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (16.6K in the company's Sep 3, 2026 report, 80.5K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Citadel Advisors LLCInstitution | 79.58% | 13,220 ADS | 13Fas of Mar 31, 2026 |
Morgan StanleyInstitution | 9.70% | 1,611 ADS | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 5.23% | 869 ADS | 13Fas of Mar 31, 2026 |
Advisor Group Holdings, Inc.Institution | 0.24% | 40 ADS | 13Fas of Mar 31, 2026 |
Armistice Capital, LLCStrategic | —9.99% of class, as filed | — | 13D/Gfiled Feb 14, 2024 ↗ |
| See all 9 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Stem
Closest software rival across solar monitoring, SCADA, and optimization.
- Pacira BioSciences
Scaled approved alternative for surgical-wound pain management.
- SolarEdge Technologies
Integrated solar monitoring and control platform for C&I assets.
- Nextpower
Utility-scale solar data, control, and predictive-O&M rival.
- Heron Therapeutics
Approved extended-release alternative for post-surgical pain.
- Fluence Energy
Renewable monitoring and energy-market optimization software rival.
- Ocular Therapeutix
Hands-free post-cataract drug-delivery alternative.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PRF Technologies | $0.9600 | +1.02% | $78.5K | — | — | 3.1 | — |
| Stem | $5.52 | +1.54% | $48.9M | — | — | 0.3 | −12.2% |
| Pacira BioSciences | $26.45 | −0.41% | $1.05B | 75.7 | 8.5 | 1.4 | +6.2% |
| SolarEdge Technologies | $33.83 | −0.27% | $2.07B | — | 92.7 | 1.6 | +19.6% |
| Nextpower | $83.00 | +0.55% | $12.52B | 21.4 | 17.2 | 3.4 | +8.2% |
| Heron Therapeutics | $0.3300 | +3.19% | $59.2M | — | — | 0.4 | +1.3% |
| Fluence Energy | $10.07 | −4.82% | $1.95B | — | — | 0.7 | +7.9% |
| Ocular Therapeutix | $10.98 | +0.64% | $2.39B | — | — | 45.8 | +0.1% |
| Median | 48.5 | 17.2 | 1.4 | +6.2% |